Compare Stocks

Date Range: 

 Annovis BioGain TherapeuticsMereo BioPharma Group plc (MPH.L)Tiziana Life SciencesAmpliphi Biosciences
SymbolNYSE:ANVSNASDAQ:GANXLON:MPHLON:TILSNYSEAMERICAN:APHB
Price Information
Current Price$23.47$10.50GBX 26.50GBX 81.50$4.17
52 Week RangeN/ABuyN/AN/AN/A
MarketRank™
Overall Score0.01.70.60.40.6
Analysis Score0.03.50.00.00.0
Community Score0.05.02.81.92.8
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationN/ABuyN/AN/AN/A
Consensus Price TargetN/A$30.00N/AN/AN/A
% Upside from Price TargetN/A185.71% upsideN/AN/AN/A
Trade Information
Market Cap$163.05 million$118.98 million£138.87 million£158.61 million$139.57 million
BetaN/AN/AN/AN/AN/A
Average Volume255,316112,108333,975748,796842,200
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
CashflowN/AN/AGBX 17.12 per shareGBX 4.67 per shareN/A
Price / CashN/AN/A1.5517.44N/A
Book ValueN/AN/AGBX 7.20 per shareGBX 3.30 per shareN/A
Price / BookN/AN/AN/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AGBX (128)GBX (5.50)N/A
Trailing P/E Ratio0.000.00N/AN/A0.00
Forward P/E Ratio∞∞∞∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A164.26%17.85%N/A
Current RatioN/AN/A2.98%1.86%N/A
Quick RatioN/AN/A2.92%1.78%N/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees21150830
Shares Outstanding6.95 million11.33 million338.71 million194.61 million33.47 million
Next Earnings Date5/11/2021 (Estimated)N/AN/A6/14/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Ampliphi Biosciences (NYSEAMERICAN:APHB) Trading 1.7% Higher Ampliphi Biosciences (NYSEAMERICAN:APHB) Trading 1.7% Higher
americanbankingnews.com - May 8 at 12:16 AM
Ampliphi Biosciences (NYSEAMERICAN:APHB) Stock Price Down 0.7%Ampliphi Biosciences (NYSEAMERICAN:APHB) Stock Price Down 0.7%
americanbankingnews.com - April 17 at 6:22 AM
Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc.,Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc.,
www.bloomberg.com - April 30 at 10:41 PM
C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.
finance.yahoo.com - May 9 at 7:45 PM
AmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J TherapeuticsAmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J Therapeutics
finance.yahoo.com - May 8 at 7:37 PM
C3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic BacteriophageC3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic Bacteriophage
www.businesswire.com - April 2 at 8:40 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHBSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB
finance.yahoo.com - March 27 at 8:26 AM
Ampliphi Biosciences (APHB) Gets a Buy Rating from H.C. WainwrightAmpliphi Biosciences (APHB) Gets a Buy Rating from H.C. Wainwright
www.smarteranalyst.com - March 26 at 7:44 PM
AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business HighlightsAmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
finance.yahoo.com - March 25 at 7:35 PM
AmpliPhi Biosciences Corporation Estimate MomentumAmpliPhi Biosciences Corporation Estimate Momentum
www.nasdaq.com - March 18 at 8:02 PM
2 Risky Stocks, But A Risk Worth Taking? – Citrix Systems, Inc. (CTXS), AmpliPhi Biosciences Corporation (APHB) - CryptoAmber2 Risky Stocks, But A Risk Worth Taking? – Citrix Systems, Inc. (CTXS), AmpliPhi Biosciences Corporation (APHB) - CryptoAmber
www.cryptoamber.com - March 13 at 8:13 AM
Instant Variation:: Costco Wholesale Corporation, (NASDAQ: COST), Selecta Biosciences, Inc., (NASDAQ: SELB), AmpliPhi Biosciences Corporation, (NYSE: APHB), Duke Realty Corporation, (NYSE: DRE) - News AlarmsInstant Variation:: Costco Wholesale Corporation, (NASDAQ: COST), Selecta Biosciences, Inc., (NASDAQ: SELB), AmpliPhi Biosciences Corporation, (NYSE: APHB), Duke Realty Corporation, (NYSE: DRE) - News Alarms
www.newsalarms.com - March 11 at 7:42 PM
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Insights and Outstanding Companies are ContraFect Corp,Inhibrx LP,Achaogen Inc,LegoChem Biosciences Inc,Melinta Therapeutics Inc,Novartis AG,AmpliPhi Biosciences Corp,Biolytics Pharma,Shionogi & Co Ltd, - Journal WorldwideGlobal Resistant Pseudomonas Aeruginosa Infections Drugs Market Insights and Outstanding Companies are ContraFect Corp,Inhibrx LP,Achaogen Inc,LegoChem Biosciences Inc,Melinta Therapeutics Inc,Novartis AG,AmpliPhi Biosciences Corp,Biolytics Pharma,Shionogi & Co Ltd, - Journal Worldwide
journalworldwide.com - February 26 at 6:44 PM
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ampliphi Biosciences (APHB)Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ampliphi Biosciences (APHB)
www.smarteranalyst.com - January 16 at 5:55 PM
AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)AmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)
seekingalpha.com - January 15 at 8:17 AM
Kansas City Southern (KSU) EPS Estimated At $1.55; Ampliphi Biosciences Has 3 Sentiment - The Hi New UlmKansas City Southern (KSU) EPS Estimated At $1.55; Ampliphi Biosciences Has 3 Sentiment - The Hi New Ulm
hinewulm.com - January 8 at 8:23 AM
Will Shareholder Love To Invest in This Stock? – AmpliPhi Biosciences Corporation (NYSE: APHB) - Bulls Watch ListWill Shareholder Love To Invest in This Stock? – AmpliPhi Biosciences Corporation (NYSE: APHB) - Bulls Watch List
www.bullswatchlist.com - January 8 at 8:23 AM
Marina del Rey-Based C3J Therapeutics Agrees to Merge With AmpliPhi BiosciencesMarina del Rey-Based C3J Therapeutics Agrees to Merge With AmpliPhi Biosciences
labusinessjournal.com - January 4 at 5:45 PM
AmpliPhi Biosciences and C3J Therapeutics Agree to MergeAmpliPhi Biosciences and C3J Therapeutics Agree to Merge
www.bizjournals.com - January 4 at 5:45 PM
AmpliPhi Bio up 45% premarket on merger with C3J TherapeuticsAmpliPhi Bio up 45% premarket on merger with C3J Therapeutics
seekingalpha.com - January 4 at 5:45 PM
AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01AmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01
seekingalpha.com - December 18 at 8:20 AM
AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical DevelopmentAmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development
finance.yahoo.com - December 18 at 8:20 AM
Ampliphi Biosciences (APHB) STOCK APHB STOCKAmpliphi Biosciences (APHB) STOCK APHB STOCK
markets.businessinsider.com - December 17 at 8:17 AM
DateCompanyBrokerageAction
4/19/2021Gain TherapeuticsBTIG ResearchInitiated Coverage
4/19/2021Gain TherapeuticsOppenheimerInitiated Coverage
11/1/2019Tiziana Life SciencesShore CapitalReiterated Rating
3/26/2019Ampliphi BiosciencesHC WainwrightReiterated Rating
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.